Skip to main content

Advertisement

Table 3 Characteristics of patients who did or did not reach the target PBG

From: Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study

  Patients who reached the target PBG using this protocol(N = 14) Patients who failed to reach the target PBG
Age (years) 67.0 (55.5-70.5) 78 61
Sex (men/women) 10/4 man woman
BMI (kg/m2) 25.0 (21.8-27.8) 28.0 22.1
Duration of diabetes (years) 13.0 (7.0-21.5) 12 40
HbA1c (%) 9.2 (8.7-11.2) 8.3 8.2
Glycated albumin (%) 23.0 (20.2-29.4) 21.1 19.8
eGFR (mL/min/1.73 m2) 70.5 (58–84.2) 70.0 67.2
Urinary C-peptide excretion (μg/day) 43.5 (24.8-69.6) 67.4 14.4
C-peptide    
(Glucagon stimulated test)    
at 0 minutes (ng/mL) 0.9 (0.75-1.45) 1.9 0.4
at 6 minutes (ng/mL) 2.3 (1.45-2.9) 3.0 0.8
Δ (ng/mL) 1.1 (0.65-1.40) 1.1 0.4
Insulin glargine (units/day) 14 (8.5-18.5) 12 13
Insulin glargine (units/kg) 0.2 (0.17-0.26) 0.15 0.23
MAGE at the final CGM evaluation 60.5 (46.9-69.2) 61.3 87.6
(N = 12)   
M-value at the final SMBG evaluation 8.4 (4.3-14.1) 24.2 18.0
  1. Median (interquartile range).